Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 20 Jun 2005 |
| Genmab, HuMax®-CD20 Induces Clinical Response in NHL at All Dose Levels | 10 Jun 2005 |
| InvestorService: Genmab, to Present at the Goldman Sachs 26th Annual Global Healthcare Conference | 9 Jun 2005 |
| Genmab, Grant of Warrants | 7 Jun 2005 |
| Genmab, changes management/auditors | 6 Jun 2005 |